Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Q2 2024 Earnings Call Transcript
Renée Aguiar-Lucander: Thank you very much. Welcome to our Q2 2024 report. My name is Renée Aguiar-Lucander, CEO of Calliditas.
No. | Hedge Fund | Shares | Value | Activity | % Port |
---|---|---|---|---|---|
1. | Biotechnology Value Fund / BVF Inc Mark Lampert | 750,000 | $29,242,500 | 0.81% | |
2. | Ironwood Investment Management Warren Isabelle | 25,627 | $999,197 | +1% | 0.53% |
3. | 8,500 | $331,415 | +467% | 0% | |
4. | 6,400 | $249,536 | -34% | 0% | |
5. | Citadel Investment Group Ken Griffin | 0 | $0 | 0% |
No. | Name | Shares | Value | % Port |
---|---|---|---|---|
1. | 50,550 | $1,301,157 | 0% | |
2. | 31,600 | $814,332 | 0% | |
3. | 14,400 | $371,088 | 0% | |
4. | 9,412 | $242,547 | 0% | |
5. | 2,000 | $51,540 | 0% |